Condensed Consolidated Statements of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($) $ in Thousands	Series 1 Convertible Preferred Stock	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Total
Balance at Dec. 31, 2019		$ 3	$ 10,651	$ (12,782)		$ (2,128)
Balance (in Shares) at Dec. 31, 2019		2,627,533
Issuance of Common Stock in ArTara Private Placement, net of offering costs			1,867			1,867
Issuance of Common Stock in ArTara Private Placement, net of offering costs (in Shares)		284,875
Issuance of Common Stock in Proteon Private Placement, net of offering costs		$ 2	12,411			12,413
Issuance of Common Stock in Proteon Private Placement, net of offering costs (in Shares)		1,896,888
Issuance of Series 1 Convertible Preferred Stock in Proteon Private Placement, net of offering costs			25,319			25,319
Issuance of Series 1 Convertible Preferred Stock in Proteon Private Placement, net of offering costs (in Shares)	3,879
Reverse business combination		$ 1	34,532			34,533
Reverse business combination (in Shares)		1,033,907
Stock-based compensation - restricted stock units			2,430			2,430
Stock-based compensation - stock options			368			368
Net loss				(10,060)		(10,060)
Balance at Mar. 31, 2020		$ 6	87,578	(22,842)		64,742
Balance (in Shares) at Mar. 31, 2020	3,879	5,843,203
Stock-based compensation - restricted stock units			1,315			1,315
Stock-based compensation - stock options			514			514
Net loss				(7,140)		(7,140)
Balance at Jun. 30, 2020		$ 6	89,407	(29,982)		59,431
Balance (in Shares) at Jun. 30, 2020	3,879	5,843,203
Stock-based compensation - restricted stock units			1,307			1,307
Settlement of restricted stock units (in Shares)		20,870
Exercise of stock options			530			530
Exercise of stock options (in Shares)		57,767
Issuance of Common Stock in public offering, net of offering costs		$ 5	73,566			73,571
Issuance of Common Stock in public offering, net of offering costs (in Shares)		4,600,000
Issuance of Series 1 Convertible Preferred in public offering, net of offering costs			66,283			66,283
Issuance of Series 1 Convertible Preferred in public offering, net of offering costs (in Shares)	4,148
Stock-based compensation - stock options			1,474			1,474
Net loss				(7,970)		(7,970)
Balance at Sep. 30, 2020		$ 11	232,567	(37,952)		194,626
Balance (in Shares) at Sep. 30, 2020	8,027	10,521,840
Balance at Dec. 31, 2020		$ 11	245,992	(46,760)		199,243
Balance (in Shares) at Dec. 31, 2020	8,027	11,211,840
Stock-based compensation - restricted stock units			1,303			1,303
Settlement of restricted stock units			(228)			(228)
Settlement of restricted stock units (in Shares)		16,766
Stock-based compensation - stock options			1,437			1,437
Unrealized gains on available-for-sale marketable debt securities					(164)	(164)
Net loss				(13,465)		(13,465)
Balance at Mar. 31, 2021		$ 11	248,504	(60,225)	(164)	188,126
Balance (in Shares) at Mar. 31, 2021	8,027	11,228,606
Stock-based compensation - restricted stock units			1,360			1,360
Settlement of restricted stock units (in Shares)		5,250
Stock-based compensation - stock options			1,638			1,638
Unrealized gains on available-for-sale marketable debt securities					63	63
Net loss				(12,782)		(12,782)
Balance at Jun. 30, 2021		$ 11	251,502	(73,007)	(101)	178,405
Balance (in Shares) at Jun. 30, 2021	8,027	11,233,856
Stock-based compensation - restricted stock units			1,307			1,307
Settlement of restricted stock units (in Shares)		1,875
Stock-based compensation - stock options			1,409			1,409
Unrealized gains on available-for-sale marketable debt securities					62	62
Net loss				(10,777)		(10,777)
Balance at Sep. 30, 2021		$ 11	$ 254,218	$ (83,784)	$ (39)	$ 170,406
Balance (in Shares) at Sep. 30, 2021	8,027	11,235,731